GSA Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,026
| Closed | -$514K | – | 1945 |
|
|
2025
Q4 | $514K | Buy |
+3,026
| New | +$464K | 0.04% | 786 |
|
|
2025
Q3 | – | Sell |
-2,618
| Closed | -$278K | – | 1876 |
|
|
2025
Q2 | $278K | Buy |
2,618
+285
| +12% | +$31K | 0.02% | 1306 |
|
|
2025
Q1 | $290K | Sell |
2,333
-1,779
| -43% | -$232K | 0.03% | 1180 |
|
|
2024
Q4 | $506K | Buy |
+4,112
| New | +$485K | 0.04% | 878 |
|
|
2024
Q1 | – | Sell |
-1,689
| Closed | -$208K | – | 1798 |
|
|
2023
Q4 | $208K | Buy |
+1,689
| New | +$211K | 0.02% | 1306 |
|
|
2023
Q3 | – | Sell |
-2,039
| Closed | -$253K | – | 1705 |
|
|
2023
Q2 | $253K | Buy |
+2,039
| New | +$274K | 0.03% | 1144 |
|
|
2022
Q2 | – | Sell |
-4,333
| Closed | -$675K | – | 1600 |
|
|
2022
Q1 | $675K | Buy |
+4,333
| New | +$629K | 0.09% | 357 |
|
|
2020
Q2 | – | Sell |
-2,950
| Closed | -$294K | – | 856 |
|
|
2020
Q1 | $294K | Buy |
2,950
+412
| +16% | +$53.3K | 0.07% | 501 |
|
|
2019
Q4 | $379K | Buy |
2,538
+64
| +3% | +$8.71K | 0.04% | 849 |
|
|
2019
Q3 | $317K | Sell |
2,474
-2,826
| -53% | -$379K | 0.04% | 853 |
|
|
2019
Q2 | $756K | Buy |
+5,300
| New | +$712K | 0.08% | 402 |
|
|
2019
Q1 | – | Sell |
-3,330
| Closed | -$413K | – | 1557 |
|
|
2018
Q4 | $413K | Buy |
+3,330
| New | +$494K | 0.05% | 656 |
|
|
2018
Q2 | – | Sell |
-2,067
| Closed | -$312K | – | 1804 |
|
|
2018
Q1 | $312K | Buy |
+2,067
| New | +$303K | 0.02% | 1296 |
|
|
2017
Q2 | – | Sell |
-2,695
| Closed | -$391K | – | 1803 |
|
|
2017
Q1 | $391K | Buy |
2,695
+379
| +16% | +$49.4K | 0.02% | 1238 |
|
|
2016
Q4 | $253K | Sell |
2,316
-3,817
| -62% | -$425K | 0.02% | 1436 |
|
|
2016
Q3 | $745K | Sell |
6,133
-4,509
| -42% | -$608K | 0.04% | 807 |
|
|
2016
Q2 | $1.5M | Buy |
10,642
+2,341
| +28% | +$345K | 0.08% | 383 |
|
|
2016
Q1 | $1.08M | Sell |
8,301
-5,214
| -39% | -$649K | 0.07% | 488 |
|
|
2015
Q4 | $1.9M | Sell |
13,515
-45,460
| -77% | -$6.3M | 0.09% | 281 |
|
|
2015
Q3 | $7.83M | Buy |
58,975
+50,564
| +601% | +$8.71M | 0.39% | 20 |
|
|
2015
Q2 | $1.48M | Sell |
8,411
-6,055
| -42% | -$1.09M | 0.06% | 583 |
|
|
2015
Q1 | $2.5M | Sell |
14,466
-7,468
| -34% | -$1.28M | 0.1% | 228 |
|
|
2014
Q4 | $3.59M | Buy |
21,934
+14,277
| +186% | +$2.37M | 0.25% | 28 |
|
|
2014
Q3 | $1.23M | Sell |
7,657
-5,167
| -40% | -$794K | 0.06% | 371 |
|
|
2014
Q2 | $1.89M | Buy |
12,824
+1,631
| +15% | +$226K | 0.08% | 287 |
|
|
2014
Q1 | $1.55M | Sell |
11,193
-9,884
| -47% | -$1.49M | 0.11% | 179 |
|
|
2013
Q4 | $2.67M | Buy |
21,077
+5,469
| +35% | +$566K | 0.21% | 60 |
|
|
2013
Q3 | $1.44M | Sell |
15,608
-9,173
| -37% | -$740K | 0.11% | 195 |
|
|
2013
Q2 | $1.7M | Buy |
+24,781
| New | +$1.51M | 0.2% | 91 |
|
Other funds holding JAZZ
VPM
VCM
EC
GSA Capital Partners's JAZZ Position: Q1 2026 in Review
GSA Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 3,026 shares — an estimated $514K sold.
GSA Capital Partners first reported a position in JAZZ in Q2 2013 and held it in 29 quarters. The position peaked at $7.83M in Q3 2015. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- GSA Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- GSA Capital Partners sold 3,026 Jazz Pharmaceuticals shares in Q1 2026, an estimated $514K.
- GSA Capital Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 29 quarters.
- GSA Capital Partners's Jazz Pharmaceuticals position peaked at $7.83M in Q3 2015.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.